Skip to main content

ESTUDIO DE LA HETEROGENEIDAD DE LA MIASTENIA GRAVIS: INVESTIGACION CLINICA Y PRECLINICA MEDIANTE LA IMPLEMENTACION DE MODELOS CELULARES 2D Y 3D Y UTILIZACION DE BIOSENSORES.

PI19/01774

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO
Execution centre IIB-SANT PAU. INSTITUTO DE INVESTIGACION HOSPITAL SANTA CRUZ Y SAN PABLO

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Drug-refractory myasthenia gravis, Clinical characteristics, treatments, and outcome

  • Cortés-Vicente, Elena|||0000-0002-1428-1072
  • Álvarez Velasco, Rodrigo|||0000-0002-4743-7205
  • Pla-Junca, Francesc
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Paradas, Carmen|||0000-0002-6917-2236
  • Sevilla, Teresa|||0000-0003-4716-2667
  • Casasnovas, Carlos|||0000-0002-7933-4681
  • Gómez-Caravaca, María Teresa
  • Pardo, Julio|||0000-0001-8807-1310
  • Ramos-Fransi, Alba|||0000-0002-4114-4575
  • Pelayo-Negro, Ana Lara
  • Gutiérrez-Gutiérrez, Gerardo
  • Turon-Sans, Janina|||0000-0002-8842-4646
  • Lopez de Munain, Adolfo|||0000-0002-9509-4032
  • Guerrero Sola, Antonio
  • Jericó-Pascual, Ivonne|||0000-0003-4262-6370
  • Martín, María Asunción
  • Mendoza, María Dolores
  • Morís, Germán|||0000-0001-7608-2194
  • Vélez-Gómez, Beatriz|||0000-0001-5796-5872
  • García-Sobrino, Tania|||0000-0001-8067-431X
  • Pascual-Goñi, Elba|||0000-0001-7336-4305
  • Reyes-Leiva, David|||0000-0001-6983-7130
  • Illa, Isabel|||0000-0002-2186-2684
  • Gallardo, Eduard|||0000-0002-3942-3436
To describe the clinical characteristics and outcomes in patients with refractory myasthenia gravis (MG) and to determine the effectiveness and side effects of the drugs used for their treatment. This observational retrospective cross-sectional multicenter study was based on data from the Spanish MG Registry (NMD-ES). Patients were considered refractory when their MG Foundation of America post-interventional status (MGFA-PIS) was unchanged or worse after corticosteroids and two or more other immunosuppressive agents. Clinical and immunologic characteristics of drug-refractory patients, efficiency and toxicity of drugs used, and outcome (MGFA-PIS) at end of follow-up were studied. We included 990 patients from 15 hospitals. Eighty-four patients (68 of 842 anti-acetylcholine receptor [AChR], 5 of 26 anti-muscle-specific tyrosine kinase [MusK], 10 of 120 seronegative, and 1 of 2 double-seropositive patients) were drug refractory. Drug-refractory patients were more frequently women (p < 0.0001), younger at onset (p < 0.0001), and anti-MuSK positive (p = 0.037). Moreover, they more frequently presented a generalized form of the disease, bulbar symptoms, and life-threatening events (p < 0.0001; p = 0.018; and p = 0.002, respectively) than non-drug-refractory patients. Mean follow-up was 9.8 years (SD 4.5). Twenty-four (50%) refractory patients had side effects to one or more of the drugs. At the end of follow-up, 42.9% of drug-refractory patients (42.6% of anti-AChR, 100% of anti-MuSK, and 10% of seronegative patients) and 79.8% of non-drug-refractory patients (p < 0.0001) achieved remission or had minimal manifestations. Eighty percent of drug-refractory-seronegative patients did not respond to any drug tested. In this study, 8.5% of MG patients were drug-refractory. New more specific drugs are needed to treat drug-refractory MG patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Reduced Number of Thymoma CTLA4-Positive Cells Is Associated With a Higher Probability of Developing Myasthenia Gravis

  • Álvarez Velasco, Rodrigo|||0000-0002-4743-7205
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • El Bounasri, Shaima|||0000-0003-0384-1633
  • López Vilaró, Laura|||0000-0002-5428-8017
  • Trujillo Reyes, Juan Carlos|||0000-0002-3370-0869
  • Reyes-Leiva, David|||0000-0001-6983-7130
  • Suarez-Calvet, Xavier|||0000-0002-5314-6607
  • Cortés-Vicente, Elena|||0000-0002-1428-1072
  • Illa, Isabel|||0000-0002-2186-2684
  • Gallardo, Eduard|||0000-0002-3942-3436
Myasthenia gravis (MG) is an autoimmune disease associated with comorbid thymoma in 10%-15% of cases. Cytotoxic T lymphocyte-associated antigen 4 (CTLA4) expressed by T cells downregulates T-cell-mediated immune response. Polymorphisms in the CTLA4 gene have been associated with the development of MG. In this context, we aimed to determine whether CTLA4 expression in the thymoma differs between patients with and without MG and whether CTLA4 gene polymorphisms are associated with these differences. This is a retrospective study of all patients, with and without MG, surgically treated at our institution for thymoma between January 2010 and December 2020. Ten samples were obtained from normal thymuses as controls. The number of CTLA4-positive cells in paraffin-embedded thymoma samples was determined by immunohistochemistry. The presence of follicular-center and regulatory T-cell lymphocytes was determined by immunohistochemistry (B-cell lymphoma [BCL]-6 expression) and double immunofluorescence-based staining of CD4-FOXP3, respectively. We evaluated the association between thymic expression of CTLA4 and the development of MG. We also determined the association between CTLA4 expression and various clinical and prognostic characteristics of MG. We sequenced the CTLA4 gene and evaluated possible associations between CTLA4 polymorphisms and thymic CTLA4 expression. Finally, we assessed the potential association between these polymorphisms and the risk of MG. Forty-one patients with thymoma were included. Of them, 23 had comorbid MG (56.1%). On average, patients with MG had fewer CTLA4-positive cells in the thymoma than non-MG patients: 69.3 cells/mm 2 (95% CIs: 39.6-99.1) vs 674.4 (276.0-1,024.0) cells/mm 2 ; p = 0.001 and vs controls (200.74 [57.9-343.6] cells/mm 2 ; p = 0.02). No between-group differences (MG vs non-MG) were observed in the number of cells positive for BCL6 or CD4-FOXP3. CTLA4 expression was not associated with differences in MG outcome or treatment refractoriness. Two polymorphisms were detected in the CTLA4 gene, rs231770 (n = 30 patients) and rs231775 (n = 17). MG was present in a similar proportion of patients for all genotypes. However, a nonsignificant trend toward a lower CTLA4-positive cell count was observed among carriers of the rs231775 polymorphism vs noncarriers: 77.9 cells/mm 2 (95% CI: -51.5 to 207.5) vs 343.3 cells/mm 2 (95% CI: 126.2-560.4). Reduced CTLA4 expression in thymoma may predispose to a higher risk of developing MG.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Immune Response and Safety of SARS-CoV-2 mRNA-1273 Vaccine in Patients With Myasthenia Gravis

  • Reyes-Leiva, David|||0000-0001-6983-7130
  • López-Contreras, Joaquín|||0000-0002-3166-4016
  • Moga, Esther|||0000-0003-4264-6910
  • Pla-Juncà, Francesc|||0000-0002-4403-6297
  • Lynton-Pons, Elionor|||0000-0001-5375-7195
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Turon-Sans, Janina|||0000-0002-8842-4646
  • Querol, Luis|||0000-0002-4289-8264
  • Olivé i Plana, Montserrat|||0000-0001-5727-0165
  • Álvarez Velasco, Rodrigo|||0000-0002-4743-7205
  • Caballero-Ávila, Marta|||0000-0001-9850-8504
  • Carbayo Viejo, Álvaro|||0000-0001-9282-8603
  • Vesperinas-Castro, Ana|||0000-0003-1919-9382
  • Domingo Pedrol, Pedro|||0000-0003-1138-5770
  • Illa, Ignacio
  • Gallardo, Eduard|||0000-0002-3942-3436
  • Cortés-Vicente, Elena|||0000-0002-1428-1072
Evidence regarding the safety and efficacy of messenger RNA (mRNA) vaccines in patients with myasthenia gravis (MG) after immunosuppressive therapies is scarce. Our aim is to determine whether the mRNA-1273 vaccine is safe and able to induce humoral and cellular responses in patients with MG. We performed an observational, longitudinal, prospective study including 100 patients with MG of a referral center for MG in our country, conducted from April 2021 to November 2021 during the vaccination campaign. The mRNA-1273 vaccine was scheduled for all participants. Blood samples were collected before vaccination and 3 months after a second dose. Clinical changes in MG were measured using the MG activities of daily life score at baseline and 1 week after the first and second doses. A surveillance of all symptoms of coronavirus disease 2019 (COVID-19) was conducted throughout the study. Humoral and cellular immune responses after vaccination were assessed using a spike-antibody ELISA and interferon gamma release assay in plasma. The primary outcomes were clinically significant changes in MG symptoms after vaccination, adverse events (AEs), and seroconversion and T-cell immune response rates. Ninety-nine patients completed the full vaccination schedule, and 98 had 2 blood samples taken. A statistically significant worsening of symptoms was identified after the first and second doses of the mRNA-1273 vaccine, but this was not clinically relevant. Mild AEs occurred in 14 patients after the first dose and in 21 patients after the second dose. Eighty-seven patients developed a humoral response and 72 patients showed a T-cell response after vaccination. A combined therapy with prednisone and other immunosuppressive drugs correlated with a lower seroconversion ratio (OR = 5.97, 95% CI 1.46-24.09, p = 0.015) and a lower T-cell response ratio (OR = 2.83, 95% CI 1.13-7.13, p = 0.024). Our findings indicate that the mRNA vaccination against COVID-19 is safe in patients with MG and show no negative impact on the disease course. Patients achieved high humoral and cellular immune response levels. This study provides Class IV evidence that patients with MG receiving the mRNA-1273 vaccine did not show clinical worsening after vaccination and that most of the patients achieved high cellular or immune response levels.